A Phase 2 interventional study of Basmisanil and Placebo in Dup15q Syndrome, sponsored by Hoffmann-La Roche. Terminated at 5 sites in 3 countries. Open to participants aged 2 Years to 14 Years. Per ClinicalTrials.gov, last updated 2026-08-18.
Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study consists of two parts. Part 1 will evaluate the safety, efficacy, and pharmacodynamics of 52-weeks of basmisanil treatment in children and adolescents (aged 2-14 years) with Dup15q syndrome. Part 1 will test the hypothesis that negative allosteric modulation of a GABAA receptor subtype can address excessive receptor function and positively impact core neurodevelopmental disease feature in individuals with Dup15q syndrome. Part 2 is an optional 2-year open-label extension to evaluate long-term safety, tolerability, and to provide supportive evidence of benefit of continued treatment with basmisanil in selected efficacy outcomes.
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive oral basmisanil twice daily (BID) on the first day of treatment, then three times per day (TID) until the end of Part 1 of the trial (Day 365) or the end of Part 2 (Day 1095)
Drug: Basmisanil
Participants will receive oral placebo BID on the first day of treatment, then TID until the end of Part 1 of the trial (Day 365).
Drug: Placebo
Participants will receive oral basmisanil at age-appropriate dosages
Participants will receive oral placebo
Vineland-3 Adaptive Behavior Scales, 3rd Edition Composite Scores
The Vineland-3 is an instrument that measures communication, daily living skills, socialization, and motor skills for those with intellectual and developmental disabilities. Items consist of open-ended questions related to activities and behavior and are scored as 2 = Usually, 1 = Sometimes, and 0 = Never. Items requiring a binary response are scored as 2 = Yes, 0. Standard scores for the adaptive behavior composite range from 20-160; lower scores indicate lower adaptive functioning.
Time frame: Baseline, Day 183, Day 365
Vineland-3 Gross and Fine Motor Subdomains Scores
The Vineland-3 is an instrument that measures communication, daily living skills, socialization, and motor skills for those with intellectual and developmental disabilities. Items consist of open-ended questions related to activities and behavior and are scored as 2 = Usually, 1 = Sometimes, and 0 = Never. Items requiring a binary response are scored as 2 = Yes, 0. V-scale scores for the gross and fine motor domains range from 1-24; lower scores indicate lower adaptive functioning.
Time frame: Baseline, Day 183, Day 365
Vineland 3 Expressive and Receptive Communication Subdomains
The Vineland-3 is an instrument that measures communication, daily living skills, socialization, and motor skills for those with intellectual and developmental disabilities. Items consist of open-ended questions related to activities and behavior and are scored as 2 = Usually, 1 = Sometimes, and 0 = Never. Items requiring a binary response are scored as 2 = Yes, 0. V-scale scores for the expressive and receptive communication subdomains range from 1-24; lower scores indicate lower adaptive functioning.
Time frame: Baseline, Day 183, Day 365
Vineland-3 Play and Leisure Time and Interpersonal Relationships Subdomains
The Vineland-3 is an instrument that measures communication, daily living skills, socialization, and motor skills for those with intellectual and developmental disabilities. Items consist of open-ended questions related to activities and behavior and are scored as 2 = Usually, 1 = Sometimes, and 0 = Never. Items requiring a binary response are scored as 2 = Yes, 0. V-scale scores for the play and leisure time, and interpersonal relationships subdomains range from 1-24; lower scores indicate lower adaptive functioning.
Time frame: Baseline, Day 153, Day 365
Mullen Scales of Early Learning (MSEL) Gross and Fine Motor Domains
The MSEL are designed for a certified rater to provide an assessment of cognitive ability and motor development of typically developing children from birth through age 68 months. It was administered to all participants in this study irrespective of their chronological age. The instrument consists of 124 items across five scales measuring Gross Motor, Visual Reception, Fine Motor, Expressive Language, and Receptive Language. Each item is scored from 0-5 points with total raw score ranges of 0-100 (gross motor) and 0-78 (fine motor). Lower score indicate lower developmental abilities; higher scores indicate greater developmental abilities.
Time frame: Baseline, Day 183, Day 365
MSEL Visual Reception Domain Scores
The MSEL are designed for a certified rater to provide an assessment of cognitive ability and motor development of typically developing children from birth through age 68 months. It was administered to all participants in this study irrespective of their chronological age. The instrument consists of 124 items across five scales measuring Gross Motor, Visual Reception, Fine Motor, Expressive Language, and Receptive Language. Each item is scored from 0-5 points with a total raw score range of 0-50. Lower score indicate lower developmental abilities; higher scores indicate greater developmental abilities.
Time frame: Baseline, Day 183
MSEL Expressive and Receptive Language Subdomains
The MSEL are designed for a certified rater to provide an assessment of cognitive ability and motor development of typically developing children from birth through age 68 months. It was administered to all participants in this study irrespective of their chronological age. The instrument consists of 124 items across five scales measuring Gross Motor, Visual Reception, Fine Motor, Expressive Language, and Receptive Language. Each item is scored from 0-5 points with a total raw score range of 0-50 (expressive language) or 0-48 (receptive language). Lower score indicate lower developmental abilities; higher scores indicate greater developmental abilities.
Time frame: Baseline, Day 183
Dup15q Syndrome Clinician Global Impression of Severity (CGI-S) Scale Scores
The Dup15q CGI-S is a 10-domain clinician-rated measure on a 6-point scale that measures global severity of illness at a given point in time. The ten domains are seizures, expressive communication difficulties, fine motor skills difficulties, gross motor skills difficulties, cognitive/intellectual impairment, impairment in activities of daily living/self-care, socialization, maladaptive behavior, sleep difficulties, and overall severity. Response options are 1-none, 2-very mild, 3-mild, 4-moderate, 5-severe, and 6-very severe.
Time frame: Baseline until Day 395, or early termination (prior to Day 395)
Dup15q Syndrome Clinician Global Impression of Change Scale (CGI-C) Scores
The Dup15q CGI-C is a 10-domain clinician-rated measure on a 7-point scale that assesses the clinician's impression of change in illness compared with baseline. The ten domains are seizures, expressive communication difficulties, fine motor skills difficulties, gross motor skills difficulties, cognitive/intellectual impairment, impairment in activities of daily living/self-care, socialization, maladaptive behavior, sleep difficulties, and overall severity. Response options are 1-very much improved, 2-much improved, 3-minimally improved, 4-no change, 5-minimally worse, 6-much worse, and 7-very much worse. The CGI does not yield a global score.
Time frame: Day 28 - Day 395 or early termination (prior to Day 395)
Aberrant Behavior Checklist - Second Edition - Community Version (ABC-2-C) Domain Scores - Irritability
The ABC-2 is an updated, empirically derived, validated 58-item caregiver-completed rating scale that measures the severity of a range of maladaptive behaviors commonly observed in children, adolescents, and adults with intellectual and developmental disabilities. The Community version of the scale (ABC-2-C) will be used. It is designed for use in individuals who are not residing in institutional settings. The checklist assesses symptoms across five domains: irritability, social withdrawal, stereotypic behavior, hyperactive/noncompliance, and inappropriate speech. Items are scored on a 4-point scale from 0 (never) to 3 (severe problem). The irritability domain score range is 0-45, with higher score indicating greater severity.
Time frame: Baseline - Day 365, or early termination (prior to Day 365)
ABC-2-C Domain Scores - Social Withdrawal
The ABC-2 is an updated, empirically derived, validated 58-item caregiver-completed rating scale that measures the severity of a range of maladaptive behaviors commonly observed in children, adolescents, and adults with intellectual and developmental disabilities. The Community version of the scale (ABC-2-C) will be used. It is designed for use in individuals who are not residing in institutional settings. The checklist assesses symptoms across five domains: irritability, social withdrawal, stereotypic behavior, hyperactive/noncompliance, and inappropriate speech. Items are scored on a 4-point scale from 0 (never) to 3 (severe problem). The social withdrawal domain score range is 0-48, with higher scores indicating greater severity.
Time frame: Baseline - Day 365, or early termination (prior to Day 365)
ABC-2-C Domain Scores - Stereotypic Behavior
The ABC-2 is an updated, empirically derived, validated 58-item caregiver-completed rating scale that measures the severity of a range of maladaptive behaviors commonly observed in children, adolescents, and adults with intellectual and developmental disabilities. The Community version of the scale (ABC-2-C) will be used. It is designed for use in individuals who are not residing in institutional settings. The checklist assesses symptoms across five domains: irritability, social withdrawal, stereotypic behavior, hyperactive/noncompliance, and inappropriate speech. Items are scored on a 4-point scale from 0 (never) to 3 (severe problem). The stereotypic behavior subdomain score range is 0-21, with higher scores indicating greater severity.
Time frame: Baseline - Day 365, or early termination (prior to Day 365)
ABC-2-C Domain Scores - Hyperactivity/Non-Compliance
The ABC-2 is an updated, empirically derived, validated 58-item caregiver-completed rating scale that measures the severity of a range of maladaptive behaviors commonly observed in children, adolescents, and adults with intellectual and developmental disabilities. The Community version of the scale (ABC-2-C) will be used. It is designed for use in individuals who are not residing in institutional settings. The checklist assesses symptoms across five domains: irritability, social withdrawal, stereotypic behavior, hyperactive/noncompliance, and inappropriate speech. Items are scored on a 4-point scale from 0 (never) to 3 (severe problem). The hyperactivity/non-compliance subdomain score range is 0-45, with higher scores indicating greater severity.
Time frame: Baseline until Day 365, or early termination (prior to Day 365)
ABC-2-C Domain Scores - Inappropriate Speech
The ABC-2 is an updated, empirically derived, validated 58-item caregiver-completed rating scale that measures the severity of a range of maladaptive behaviors commonly observed in children, adolescents, and adults with intellectual and developmental disabilities. The Community version of the scale (ABC-2-C) will be used. It is designed for use in individuals who are not residing in institutional settings. The checklist assesses symptoms across five domains: irritability, social withdrawal, stereotypic behavior, hyperactive/noncompliance, and inappropriate speech. Items are scored on a 4-point scale from 0 (never) to 3 (severe problem). The inappropriate speech subdomain score range is 0-12, with higher scores indicating greater severity.
Time frame: Baseline until Day 365, or early termination (prior to Day 365)
Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)
An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.
Time frame: Up to 52 weeks
Plasma Concentration of Basmisanil
Time frame: Day 1 - Day 183
Plasma Concentration of the Basmisanil Metabolite M1
Time frame: Day 1 - Day 183
Quantitative EEG (qEEG) Beta-band Power
This is the average of the EEG parameter 10 x Log\_10 of the total beta power between 16 and 32 Hz in microVolt\^2.
Time frame: Baseline, Day 14
| Milestone | Placebo | Basmisanil |
|---|---|---|
| Started | 2 | 5 |
| Completed | 0 | 0 |
| Not completed | 2 | 5 |
| Withdrew: Study terminated by sponsor or physician decision | 2 | 5 |
The Vineland-3 is an instrument that measures communication, daily living skills, socialization, and motor skills for those with intellectual and developmental disabilities. Items consist of open-ended questions related to activities and behavior and are scored as 2 = Usually, 1 = Sometimes, and 0 = Never. Items requiring a binary response are scored as 2 = Yes, 0. Standard scores for the adaptive behavior composite range from 20-160; lower scores indicate lower adaptive functioning.
| Units on a scale | Placebo | Basmisanil |
|---|---|---|
| Baseline | 30.50 (30.0 to 31.0) | 36.00 (27.0 to 52.0) |
| Day 183 | 28.00 (28.0 to 28.0) | 32.00 (32.00 to 32.00) |
| Day 365 | 32.00 (32.00 to 32.00) | — |
The Vineland-3 is an instrument that measures communication, daily living skills, socialization, and motor skills for those with intellectual and developmental disabilities. Items consist of open-ended questions related to activities and behavior and are scored as 2 = Usually, 1 = Sometimes, and 0 = Never. Items requiring a binary response are scored as 2 = Yes, 0. V-scale scores for the gross and fine motor domains range from 1-24; lower scores indicate lower adaptive functioning.
| Units on a scale | Placebo | Basmisanil |
|---|---|---|
| Gross Motor V-Scale Score - Baseline | 1.00 (1.0 to 1.0) | 4.50 (1.0 to 8.0) |
| Gross Motor V-Scale Score - Day 183 | 4.00 (4.00 to 4.00) | — |
| Gross Motor V-Scale Score - Day 365 | 1.00 (1.0 to 1.0) | — |
| Fine Motor V-Scale Score - Baseline | 1.00 (1.0 to 1.0) | 3.00 (1.0 to 5.0) |
| Fine Motor V-Scale Score - Day 183 | 1.00 (1.00 to 1.00) | — |
| Fine Motor V-Scale Score - Day 365 | 1.00 (1.00 to 1.00) | — |
The Vineland-3 is an instrument that measures communication, daily living skills, socialization, and motor skills for those with intellectual and developmental disabilities. Items consist of open-ended questions related to activities and behavior and are scored as 2 = Usually, 1 = Sometimes, and 0 = Never. Items requiring a binary response are scored as 2 = Yes, 0. V-scale scores for the expressive and receptive communication subdomains range from 1-24; lower scores indicate lower adaptive functioning.
| Units on a scale | Placebo | Basmisanil |
|---|---|---|
| Expressive Communication V-Scale Score - Baseline | 1.00 (1.0 to 1.0) | 1.00 (1.0 to 11.0) |
| Expressive Communication V-Scale Score - Day 183 | 1.00 (1.0 to 1.0) | 1.00 (1.0 to 1.0) |
| Expressive Communication V-Scale Score - Day 365 | 1.00 (1.0 to 1.0) | — |
| Receptive Communication V-Scale Score - Baseline | 1.00 (1.0 to 1.0) | 1.00 (1.0 to 6.0) |
| Receptive Communication V-Scale Score - Day 183 | 1.00 (1.0 to 1.0) | 1.00 (1.0 to 1.0) |
| Receptive Communication V-Scale Score - Day 365 | 1.00 (1.0 to 1.0) | — |
The Vineland-3 is an instrument that measures communication, daily living skills, socialization, and motor skills for those with intellectual and developmental disabilities. Items consist of open-ended questions related to activities and behavior and are scored as 2 = Usually, 1 = Sometimes, and 0 = Never. Items requiring a binary response are scored as 2 = Yes, 0. V-scale scores for the play and leisure time, and interpersonal relationships subdomains range from 1-24; lower scores indicate lower adaptive functioning.
| Units on a scale | Placebo | Basmisanil |
|---|---|---|
| Play and Leisure V-Scale Score - Baseline | 1.00 (1.0 to 1.0) | 1.00 (1.0 to 9.0) |
| Play and Leisure V-Scale Score - Day 183 | 1.00 (1.0 to 1.0) | 1.00 (1.0 to 1.0) |
| Play and Leisure V-Scale Score - Day 365 | 1.00 (1.0 to 1.0) | — |
| Interpersonal Relationships V-Scale Score - Baseline | 1.50 (1.0 to 2.0) | 1.00 (1.0 to 9.0) |
| Interpersonal Relationships V-Scale Score - Day 183 | 3.00 (3.0 to 3.0) | 1.00 (1.0 to 1.0) |
| Interpersonal Relationships V-Scale Score - Day 365 | 3.00 (3.0 to 3.0) | — |
The MSEL are designed for a certified rater to provide an assessment of cognitive ability and motor development of typically developing children from birth through age 68 months. It was administered to all participants in this study irrespective of their chronological age. The instrument consists of 124 items across five scales measuring Gross Motor, Visual Reception, Fine Motor, Expressive Language, and Receptive Language. Each item is scored from 0-5 points with total raw score ranges of 0-100 (gross motor) and 0-78 (fine motor). Lower score indicate lower developmental abilities; higher scores indicate greater developmental abilities.
| Units on a scale | Placebo | Basmisanil |
|---|---|---|
| Gross Motor - Baseline | 20.50 (14.0 to 27.0) | 19.00 (13.0 to 35.0) |
| Gross Motor - Day 183 | 24.00 (24.0 to 24.0) | 18.00 (18.0 to 18.0) |
| Gross Motor - Day 365 | 1.00 (1.0 to 1.0) | — |
| Fine Motor - Baseline | 15.50 (13.0 to 18.0) | 15.00 (6.0 to 30.0) |
| Fine Motor - Day 183 | 18.00 (18.0 to 18.0) | 9.00 (9.0 to 9.0) |
| Fine Motor - Day 365 | 11.00 (11.0 to 11.0) | — |
The MSEL are designed for a certified rater to provide an assessment of cognitive ability and motor development of typically developing children from birth through age 68 months. It was administered to all participants in this study irrespective of their chronological age. The instrument consists of 124 items across five scales measuring Gross Motor, Visual Reception, Fine Motor, Expressive Language, and Receptive Language. Each item is scored from 0-5 points with a total raw score range of 0-50. Lower score indicate lower developmental abilities; higher scores indicate greater developmental abilities.
| Units on a scale | Placebo | Basmisanil |
|---|---|---|
| Baseline | 14.00 (11.0 to 17.0) | 4.00 (2.0 to 42.0) |
| Day 183 | 21.00 (21.0 to 21.0) | 5.00 (5.0 to 5.0) |
| Day 365 | 13.00 (13.0 to 13.0) | — |
The MSEL are designed for a certified rater to provide an assessment of cognitive ability and motor development of typically developing children from birth through age 68 months. It was administered to all participants in this study irrespective of their chronological age. The instrument consists of 124 items across five scales measuring Gross Motor, Visual Reception, Fine Motor, Expressive Language, and Receptive Language. Each item is scored from 0-5 points with a total raw score range of 0-50 (expressive language) or 0-48 (receptive language). Lower score indicate lower developmental abilities; higher scores indicate greater developmental abilities.
| Units on a scale | Placebo | Basmisanil |
|---|---|---|
| Expressive Language - Baseline | 12.50 (12.0 to 13.0) | 17.00 (6.0 to 29.0) |
| Expressive Language - Day 183 | 23.00 (23.0 to 23.0) | 6.00 (6.0 to 6.0) |
| Expressive Language - Day 365 | 7.00 (7.0 to 7.0) | — |
| Receptive Language - Baseline | 10.00 (7.0 to 13.0) | 16.00 (9.0 to 28.0) |
| Receptive Language - Day 183 | 17.00 (17.0 to 17.0) | 11.00 (11.0 to 11.0) |
| Receptive Language - Day 365 | 13.00 (13.0 to 13.0) | — |
The Dup15q CGI-S is a 10-domain clinician-rated measure on a 6-point scale that measures global severity of illness at a given point in time. The ten domains are seizures, expressive communication difficulties, fine motor skills difficulties, gross motor skills difficulties, cognitive/intellectual impairment, impairment in activities of daily living/self-care, socialization, maladaptive behavior, sleep difficulties, and overall severity. Response options are 1-none, 2-very mild, 3-mild, 4-moderate, 5-severe, and 6-very severe.
| Units on a scale | Placebo | Basmisanil |
|---|---|---|
| Baseline | 4.00 (4.0 to 4.0) | 4.00 (4.0 to 6.0) |
| Day 28 | 4.00 (4.0 to 4.0) | 4.00 (3.0 to 6.0) |
| Day 92 | 4.00 (4.0 to 4.0) | 4.00 (4.0 to 6.0) |
| Day 183 | 4.00 (4.0 to 4.0) | 4.00 (4.0 to 4.0) |
| Day 274 | 4.00 (4.0 to 4.0) | — |
| Day 365 | 4.00 (4.0 to 4.0) | — |
| Follow-Up Day 395 | — | 5.00 (4.0 to 6.0) |
| Early Termination | — | 6.00 (6.0 to 6.0) |
The Dup15q CGI-C is a 10-domain clinician-rated measure on a 7-point scale that assesses the clinician's impression of change in illness compared with baseline. The ten domains are seizures, expressive communication difficulties, fine motor skills difficulties, gross motor skills difficulties, cognitive/intellectual impairment, impairment in activities of daily living/self-care, socialization, maladaptive behavior, sleep difficulties, and overall severity. Response options are 1-very much improved, 2-much improved, 3-minimally improved, 4-no change, 5-minimally worse, 6-much worse, and 7-very much worse. The CGI does not yield a global score.
| Units on a scale | Placebo | Basmisanil |
|---|---|---|
| Day 28 | 3.50 (3.0 to 4.0) | 3.00 (2.0 to 3.0) |
| Day 92 | 3.00 (3.0 to 3.0) | 3.00 (2.0 to 4.0) |
| Day 183 | 4.00 (4.0 to 4.0) | 3.00 (3.0 to 3.0) |
| Day 274 | 4.00 (4.0 to 4.0) | — |
| Day 365 | 3.00 (3.0 to 3.0) | — |
| Follow-Up Day 395 | — | 3.00 (3.0 to 4.0) |
| Early Termination | — | 4.00 (4.0 to 4.0) |
The ABC-2 is an updated, empirically derived, validated 58-item caregiver-completed rating scale that measures the severity of a range of maladaptive behaviors commonly observed in children, adolescents, and adults with intellectual and developmental disabilities. The Community version of the scale (ABC-2-C) will be used. It is designed for use in individuals who are not residing in institutional settings. The checklist assesses symptoms across five domains: irritability, social withdrawal, stereotypic behavior, hyperactive/noncompliance, and inappropriate speech. Items are scored on a 4-point scale from 0 (never) to 3 (severe problem). The irritability domain score range is 0-45, with higher score indicating greater severity.
| Units on a scale | Placebo | Basmisanil |
|---|---|---|
| Baseline | 11.00 (11.0 to 11.0) | 15.00 (3.0 to 40.0) |
| Day 28 | 10.00 (6.0 to 14.0) | 15.00 (5.0 to 18.0) |
| Day 92 | 17.00 (17.0 to 17.0) | 16.00 (5.0 to 23.0) |
| Day 183 | 20.00 (20.0 to 20.0) | 28.00 (28.0 to 28.0) |
| Day 274 | 16.00 (16.0 to 16.0) | — |
| Day 365 | 13.00 (13.0 to 13.0) | — |
| Early Termination | — | 3.00 (3.0 to 3.0) |
The ABC-2 is an updated, empirically derived, validated 58-item caregiver-completed rating scale that measures the severity of a range of maladaptive behaviors commonly observed in children, adolescents, and adults with intellectual and developmental disabilities. The Community version of the scale (ABC-2-C) will be used. It is designed for use in individuals who are not residing in institutional settings. The checklist assesses symptoms across five domains: irritability, social withdrawal, stereotypic behavior, hyperactive/noncompliance, and inappropriate speech. Items are scored on a 4-point scale from 0 (never) to 3 (severe problem). The social withdrawal domain score range is 0-48, with higher scores indicating greater severity.
| Units on a scale | Placebo | Basmisanil |
|---|---|---|
| Baseline | 14.50 (11.0 to 18.0) | 16.00 (2.0 to 25.0) |
| Day 28 | 7.50 (6.0 to 9.0) | 14.00 (7.0 to 17.0) |
| Day 92 | 10.00 (10.0 to 10.0) | 12.00 (6.0 to 24.0) |
| Day 183 | 10.00 (10.0 to 10.0) | 7.00 (7.0 to 7.0) |
| Day 274 | 2.00 (2.0 to 2.0) | — |
| Day 365 | 4.00 (4.0 to 4.0) | — |
| Early Termination | — | 22.00 (22.0 to 22.0) |
The ABC-2 is an updated, empirically derived, validated 58-item caregiver-completed rating scale that measures the severity of a range of maladaptive behaviors commonly observed in children, adolescents, and adults with intellectual and developmental disabilities. The Community version of the scale (ABC-2-C) will be used. It is designed for use in individuals who are not residing in institutional settings. The checklist assesses symptoms across five domains: irritability, social withdrawal, stereotypic behavior, hyperactive/noncompliance, and inappropriate speech. Items are scored on a 4-point scale from 0 (never) to 3 (severe problem). The stereotypic behavior subdomain score range is 0-21, with higher scores indicating greater severity.
| Units on a scale | Placebo | Basmisanil |
|---|---|---|
| Baseline | 8.00 (8.0 to 8.0) | 6.00 (0.0 to 15.0) |
| Day 28 | 5.50 (5.0 to 6.0) | 13.00 (7.0 to 16.0) |
| Day 92 | 6.00 (6.0 to 6.0) | 14.00 (8.0 to 15.0) |
| Day 183 | 4.00 (4.0 to 4.0) | 6.00 (6.0 to 6.0) |
| Day 274 | 8.00 (8.0 to 8.0) | — |
| Day 365 | 2.00 (2.0 to 2.0) | — |
| Early Termination | — | 11.00 (11.0 to 11.0) |
The ABC-2 is an updated, empirically derived, validated 58-item caregiver-completed rating scale that measures the severity of a range of maladaptive behaviors commonly observed in children, adolescents, and adults with intellectual and developmental disabilities. The Community version of the scale (ABC-2-C) will be used. It is designed for use in individuals who are not residing in institutional settings. The checklist assesses symptoms across five domains: irritability, social withdrawal, stereotypic behavior, hyperactive/noncompliance, and inappropriate speech. Items are scored on a 4-point scale from 0 (never) to 3 (severe problem). The hyperactivity/non-compliance subdomain score range is 0-45, with higher scores indicating greater severity.
| Units on a scale | Placebo | Basmisanil |
|---|---|---|
| Baseline | 32.00 (23.0 to 41.0) | 19.00 (13.0 to 38.0) |
| Day 28 | 12.00 (6.0 to 18.0) | 22.00 (15.0 to 33.0) |
| Day 92 | 40.00 (40.0 to 40.0) | 18.00 (14.0 to 35.0) |
| Day 183 | 39.00 (39.0 to 39.0) | 18.00 (18.0 to 18.0) |
| Day 274 | 40.00 (40.0 to 40.0) | — |
| Day 365 | 33.00 (33.0 to 33.0) | — |
| Early Termination | — | 14.00 (14.0 to 14.0) |
The ABC-2 is an updated, empirically derived, validated 58-item caregiver-completed rating scale that measures the severity of a range of maladaptive behaviors commonly observed in children, adolescents, and adults with intellectual and developmental disabilities. The Community version of the scale (ABC-2-C) will be used. It is designed for use in individuals who are not residing in institutional settings. The checklist assesses symptoms across five domains: irritability, social withdrawal, stereotypic behavior, hyperactive/noncompliance, and inappropriate speech. Items are scored on a 4-point scale from 0 (never) to 3 (severe problem). The inappropriate speech subdomain score range is 0-12, with higher scores indicating greater severity.
| Units on a scale | Placebo | Basmisanil |
|---|---|---|
| Baseline | 5.00 (2.0 to 8.0) | 2.00 (0.0 to 10.0) |
| Day 28 | 1.50 (0.0 to 3.0) | 0.00 (0.0 to 2.0) |
| Day 92 | 3.00 (3.0 to 3.0) | 0.00 (0.0 to 8.0) |
| Day 183 | 1.00 (1.0 to 1.0) | 0.00 (0.0 to 0.0) |
| Day 274 | 3.00 (3.0 to 3.0) | — |
| Day 365 | 2.00 (2.0 to 2.0) | — |
| Early Termination | — | 0.00 (0.0 to 0.0) |
An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.
| Count of Participants | Placebo | Basmisanil |
|---|---|---|
| AEs | 2 | 5 |
| SAEs | 0 | 1 |
| ng/mL | Basmisanil |
|---|---|
| Day 1 - Hour 1.5 | 2520 ± 965 |
| Day 1 - Hour 3.5 | 2220 ± 955 |
| Day 1 - Hour 5.5 | 1640 ± 756 |
| Day 1 - Hour 7.5 | 1040 ± 392 |
| Day 1 - Hour 9 | 791 ± 368 |
| Day 2 - Hour 0 | 731 ± 535 |
| Day 2 - Hour 1.5 | 2380 ± 576 |
| Day 2 - Hour 3.5 | 2210 ± 864 |
| Day 14 - Hour -1.5 | 1210 ± 1230 |
| Day 14 - Hour 0 | 902 ± 973 |
| Day 14 - Hour 1.5 | 2480 ± 355 |
| Day 14 - Hour 3.5 | 2160 ± 698 |
| Day 92 - Hour 0 | 896 ± 689 |
| ng/mL | Basmisanil |
|---|---|
| Day 1 - Hour 1.5 | 1410 ± 585 |
| Day 1 - Hour 3.5 | 1510 ± 417 |
| Day 1 - Hour 5.5 | 985 ± 335 |
| Day 1 - Hour 7.5 | 675 ± 221 |
| Day 1 - Hour 9 | 535 ± 173 |
| Day 2 - Hour 0 | 664 ± 568 |
| Day 2 - Hour 1.5 | 1330 ± 358 |
| Day 2 - Hour 3.5 | 1410 ± 506 |
| Day 14 - Hour -1.5 | 1400 ± 1410 |
| Day 14 - Hour 0 | 1060 ± 1470 |
| Day 14 - 1.5 | 1510 ± 413 |
| Day 14 - Hour 3.5 | 1250 ± 540 |
| Day 92 - Hour 0 | 648 ± 522 |
This is the average of the EEG parameter 10 x Log\_10 of the total beta power between 16 and 32 Hz in microVolt\^2.
| µV2 | Placebo | Basmisanil |
|---|---|---|
| Baseline | 9.47 ± 0.21 | 11.39 ± 1.55 |
| Day 14 | 9.44 ± 0.37 | 9.74 ± 1.05 |
Collected over Baseline - Day 365. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/2 (0%) | 0/2 (0%) | 2/2 (100%) |
| Basmisanil | 0/5 (0%) | 1/5 (20%) | 5/5 (100%) |
| Event | Placebo | Basmisanil |
|---|---|---|
| Unspecified SAEGeneral disorders | 0/2 | 1/5 |
| Event | Placebo | Basmisanil |
|---|---|---|
| Incorrect dose administeredInjury, poisoning and procedural complications | 2/2 | 3/5 |
| Unspecified AEGeneral disorders | 1/2 | 2/5 |
| Age, Continuous(Years) | Placebo | Basmisanil | Total |
|---|---|---|---|
| Mean | 8.0 ± 1.4 | 8.8 ± 2.2 | 8.6 ± 1.9 |
| Sex/Gender, Customized(Count of Participants) | Placebo | Basmisanil | Total |
|---|---|---|---|
| Female + Male | 2 | 5 | 7 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Basmisanil | Total |
|---|---|---|---|
| Hispanic or Latino | — | — | 0 |
| Not Hispanic or Latino | — | — | 0 |
| Unknown or Not Reported | — | — | 0 |
| Race (NIH/OMB)(Participants) | Placebo | Basmisanil | Total |
|---|---|---|---|
| American Indian or Alaska Native | — | — | 0 |
| Asian | — | — | 0 |
| Native Hawaiian or Other Pacific Islander | — | — | 0 |
| Black or African American | — | — | 0 |
| White | — | — | 0 |
| More than one race | — | — | 0 |
| Unknown or Not Reported | — | — | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).
Ran from Dec 2022 to primary completion in Mar 2024, 14 months.
Results were first posted in Dec 2025, 1 year 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Basmisanil
Polyposis Syndrome, Hereditary Mixed, 1